3 patients on ph1 had 2mg doses then moved onto 4mg one of those patients died then a further 3 more patients have had only 4mg doses and one of those patients also died..as of investor day 4 patients from ph1 were alive of those 4 2 have desease progression one no desease and one the patient of interest who's lung tumours regressed has had a differential response
Great question and can i further add completely ramp free whether our BOD has any duty of care to advise us of any patients in trial not making it through. Thankfully i believe not, and can you only imagine if one had not during The Civil War here just recently.
Good to think of our patients once in a while, not just triallists.
because the flu structure target does not change only very slight changes to its DNA each year. With Cancer each target is a different cell structure. So its like saying you have a vacine for the Flu thats approved now can i have one for the Norovirus with out testing ....so two trials from the start would have to be undertaken, and all the same preclinical testing would have to be done.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.